The Lyt phenotype of the T cells responsible for in vivo tumor rejection in syngeneic mice.
Spleen cells of BALB/c mice hyperimmunized with a transplantable methylcholanthrene-induced sarcoma Meth A (Meth A-Im-SPL) inhibited the growth of Meth A tumor in vivo in a tumor neutralizing test. Meth A-Im-SPL did not neutralize another antigenically distinct sarcoma, Meth 1, indicating that the antitumor activity is tumor specific. Lyt-1+2- cells of Meth A-Im-SPL (Im-Lyt-1+2-) were the effectors since in vitro treatment of Meth A-Im-SPL with anti-Thy 1.2 or anti-Lyt 1.2 antibody plus complement completely abrogated their neutralizing activity, whereas treatment with anti-Lyt 2.2 plus complement did not. To further confirm the effector activity of Im-Lyt-1+2- cells, T cell subpopulations were separated from Meth A-Im-SPL by the panning method. The purified Im-Lyt-1+2-, but not Im-Lyt-1+2+ cells neutralized the tumor in athymic nu/nu mice as efficiently as in +/+ mice, suggesting that the donor Im-Lyt-1+2- cells but not recipient T cells were primarily responsible for neutralizing the tumor. The present study, however, did not exclude the possible contribution of recipient T cells to the tumor neutralization and this is open to further investigation.
D000818:Animals; D000911:Antibodies, Monoclonal; D000918:Antibody Specificity; D000950:Antigens, Ly / Q000032:analysis*; D003165:Complement System Proteins / Q000276:immunology; D005260:Female; D005455:Fluorescent Antibody Technique; D006084:Graft Rejection; D008748:Methylcholanthrene; D051379:Mice; D008807:Mice, Inbred BALB C; D010641:Phenotype; D012513:Sarcoma, Experimental / Q000139:chemically induced / Q000276:immunology* / Q000473:pathology; D013154:Spleen / Q000166:cytology; D013601:T-Lymphocytes / Q000145:classification*
D000911:Antibodies, Monoclonal; D000950:Antigens, Ly; D008748:Methylcholanthrene; D003165:Complement System Proteins